Literature DB >> 690689

Myopathy associated with epsilon-aminocaproic acid (EACA) therapy. Report of two cases.

A R MacKay, H Sang U, P R Weinstein.   

Abstract

The association of myopathy with epsilon-aminocaproic acid (EACA) treatment after subarachnoid hemorrhage in two cases is reported. Clinical and laboratory findings and possible mechanisms are discussed in light of the known pharmacology of the drug. Recovery ensues if EACA treatment is terminated as soon as myopathy appears.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 690689     DOI： 10.3171/jns.1978.49.4.0597

Source DB:  PubMed          Journal:  J Neurosurg        ISSN： 0022-3085            Impact factor:   5.115


  5 in total

Review 1.  Antifibrinolytic agents in subarachnoid haemorrhage.

Authors:  K W Lindsay
Journal:  J Neurol       Date:  1987-01       Impact factor: 4.849

Review 2.  Inhibitors of fibrinolysis in the treatment of haemophilia.

Authors:  C R Rizza
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1980

Review 3.  Adverse effects of drugs on muscle.

Authors:  F L Mastaglia
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

Review 4.  Antifibrinolytic therapy to prevent early rebleeding after subarachnoid hemorrhage.

Authors:  Mark Chwajol; Robert M Starke; Grace H Kim; Stephan A Mayer; E Sander Connolly
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

5.  Why may epsilon-aminocaproic acid (EACA) induce myopathy in man? Report of a case and literature review.

Authors:  G Galassi; M Gibertoni; L Corradini; A Colombo
Journal:  Ital J Neurol Sci       Date:  1983-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.